Cryo Cell International Inc CCEL
We take great care to ensure that the data presented and summarized in this overview for CRYO CELL INTERNATIONAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CCEL
View all-
Hamilton Lane Advisors LLC410KShares$3.22 Million3.11% of portfolio
-
Sfi Advisors, LLC Montclair, NJ165KShares$1.3 Million0.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA117KShares$920,4430.0% of portfolio
-
Massmutual Trust CO Fsb111KShares$873,8450.02% of portfolio
-
Geode Capital Management, LLC Boston, MA39.9KShares$313,6980.0% of portfolio
-
Northern Trust Corp Chicago, IL38.9KShares$306,1580.0% of portfolio
-
Heron Bay Capital Management31.8KShares$249,9980.05% of portfolio
-
Cerity Partners LLC New York, NY19.6KShares$153,9600.0% of portfolio
-
Maryland Capital Management Towson, MD19.6KShares$153,9600.01% of portfolio
-
Creative One Wealth, LLC Overland Park, KS15.3KShares$120,4890.0% of portfolio
Latest Institutional Activity in CCEL
Top Purchases
Top Sells
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Insider Transactions at CCEL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2024
|
Oleg Mikulinsky Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.16%
|
$60,000
$3.77 P/Share
|
|
Nov 18
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
534
+0.12%
|
$2,136
$4.88 P/Share
|
|
Nov 17
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
516
+0.22%
|
$2,064
$4.9 P/Share
|
|
Nov 15
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
9,491
+3.97%
|
$37,964
$4.8 P/Share
|
|
Nov 15
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Open market or private sale
|
Direct |
16,000
-0.98%
|
$64,000
$4.81 P/Share
|
|
Nov 14
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.35%
|
$40,000
$4.8 P/Share
|
|
Nov 14
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.2%
|
$40,000
$4.8 P/Share
|
|
Nov 11
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
6,000
+1.42%
|
$24,000
$4.79 P/Share
|
|
Nov 11
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Open market or private sale
|
Direct |
9,495
-0.38%
|
$37,980
$4.79 P/Share
|
|
Nov 10
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Other acquisition or disposition
|
Indirect |
19,096
-100.0%
|
-
|
|
Nov 10
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
3,850
+3.19%
|
$15,400
$4.9 P/Share
|
|
Nov 10
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Open market or private sale
|
Direct |
5,505
-0.22%
|
$22,020
$4.94 P/Share
|
|
Nov 08
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Open market or private purchase
|
Indirect |
20,000
+7.05%
|
$80,000
$4.89 P/Share
|
|
Nov 08
2022
|
David Portnoy Chairman, Co-CEO |
SELL
Open market or private sale
|
Direct |
15,000
-0.87%
|
$75,000
$5.03 P/Share
|
|
Aug 31
2022
|
Harold D. Berger |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+13.92%
|
$30,000
$2.18 P/Share
|
|
Aug 25
2022
|
Oleg Mikulinsky Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+19.17%
|
$60,000
$3.2 P/Share
|
|
Aug 25
2022
|
David Portnoy Chairman, Co-CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
70,270
+7.55%
|
$210,810
$3.14 P/Share
|
|
Aug 25
2022
|
Mark L. Portnoy Co-CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,459
+6.75%
|
$178,377
$3.14 P/Share
|
|
Jul 07
2022
|
Harold D. Berger |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+17.48%
|
$15,000
$2.04 P/Share
|
|
Dec 28
2021
|
Oleg Mikulinsky Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.45%
|
$30,000
$3.2 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 20K shares |
|---|